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Background: Even with an adequate pain assessment, critically ill patients under sedation experience pain during
procedures in the intensive care unit (ICU). We evaluated the effects of adjunctive administration of Remifentanil, a
short-acting drug, in deeply sedated patient on variation of Bispectral Index (BIS) during a fiberoptic bronchoscopy.
Methods: A prospective, randomized, blinded, placebo-controlled study was conducted in 18-bed ICU. Patients
needing a tracheal fibroscopy under deep sedation (midazolam (0.1 mg/kg per hour) fentanyl (4 μg/kg per hour))
and neuromuscular blocking (atracurium 0.5 mg/kg) were included in the study. A continuous monitoring of BIS,
arterial pressure, and heart rate were realized before, during, and after the fiberoptic exam. An adjunctive
continuous placebo or Remifentanil infusion was started just before the fiberoptic exam with a target effect-site
concentration of 4 ng/ml using a Base Primea pump.
Results: Mean arterial pressure and heart rates were comparable between the placebo and Remifentanil groups at
all times of the procedure. We did not observe differences in the variation of BIS values between the two groups
during procedure. We described no change in BIS values relative to the placebo group in this population.
Conclusions: In deeply sedated and paralyzed patients, receiving analgesic support based on a scale score an
additional administration of short-acting analgesic drug, such as Remifentanil, seems not to be necessary for acute
pain control.
Trial registration: NCT00162591.
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Pain, as it relates to care procedures, such as tracheal
suction, mobilization, or wound care, is common in crit-
ically ill patients [1]. As such, it may have a negative im-
pact on patient comfort and can contribute to the
development of posttraumatic stress disorder at inten-
sive care discharge. The Behavioral Pain Scale (BPS), by
evaluating facial expressions, upper limb movements,
and compliance with mechanical ventilation, has been
developed and validated to assess pain in mechanically
ventilated, noncommunicating patients [2,3]. Units that* Correspondence: quintardherve@gmail.com
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in any medium, provided the original work is phave implemented such pain monitoring procedures in
daily patient care have reported decreases in hospital
stays and in the number of ventilation days [4]. Even in
properly sedated patients, however, variations on BPS
scores have been described during a short painful pro-
cedure [5]. This suggests the need to optimize proced-
ural pain control. Unfortunately in some situations, such
as administration of muscle relaxants, this clinical scale
cannot be used. Data indicate that variations of the Bis-
pectral Index (BIS), initially developed to monitor the
depth of anesthesia in the operating room, may be of
interest to reflect cortical arousal associated with a pain-
ful procedure in mechanically ventilated, sedated, paral-
yzed patients [6].s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Study design.
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http://www.annalsofintensivecare.com/content/2/1/29Remifentanil, a short-acting opioid, is a particularly
interesting option for the treatment of procedural pain
in critically ill patients, due to its rapid onset and dur-
ation of action and metabolism independent of hepatic
and renal status [7-9]. However, few data are available
about its use in short painful procedure in ICUs [10].
The purpose of this study was to evaluate the effects
of an adjunctive administration of Remifentanil on BIS
variations during a short, painful procedure, such as
fiberoptic bronchoscopy, in deeply sedated, paralyzed,
mechanically ventilated patients.
Methods
This single-center (surgical and medical ICU recruit-
ment), prospective, randomized, blinded, placebo-
controlled study was approved by the Ethics Committee
of the CHU of Nice, France (n° 06.027, Chairperson R.
Collomp) on August 11, 2006, and written, informed
consent was obtained from the families of the patients.
Our study followed the CONSORT recommendations
concerning the report of randomized trials. Inclusion
criteria were: mechanically ventilated patient under sed-
ation for Acute Respiratory Distress Syndrome (ARDS)
needing an endotracheal fiberoptic bronchoscopy with
alveolar lavage with use of muscle relaxants. Exclusion
criteria were: evolving intracranial disease (brain injury,
brain tumor, abscess, stroke, or hemorrhage). The sed-
ation protocol was the same for all patients, and con-
sisted of intravenous midazolam (0.1 mg/kg per hour)
and fentanyl (1.5 μg/kg per hour). Drugs were adminis-
tered continuously and their administration rates
adapted step by step, ±0.03 mg/kg/h for midazolam and
±0.3 μg/kg/h for fentanyl, to the patient’s needs in ac-
cordance with a standard protocol using the Sedation
Agitation Scale (SAS) (Appendix) [11] and the Behavior
Pain Scale (BPS) [5] before neuromuscular blocking.
This strategy was in accordance with the 2007 French
Society of Critical Care guidelines [12]. The SAS and
BPS targets before neuromuscular blocking were 1 and 3
(T0), respectively. BIS values were continuously
recorded using BIS-XP (software version 3.12), devel-
oped by Aspect Medical SystemW, and routine
hemodynamic monitoring was performed with the Phi-
lipsW Intellivue monitor. When the SAS and BPS goals
were reached, BIS was continuously recorded for 15
minutes (LB0-15). Patients were unrestricted rando-
mized, in a double-blinded fashion, into two groups: pla-
cebo or Remifentanil group. Then, a neuromuscular
blocking agent (atracurium 0.5 mg/kg) was injected in
minutes to minimize nonspecific histamine release.
Neuromuscular blocking agents were systematically used
to optimize ventilation during procedure and for
optimization of the fiberoptic bronchoscopy [13]. Train
of Four (TOF) responses of the left and right orbiculariswere recorded (C0-C10). At the same time (T1), either
Remifentanil or the placebo was given at a target effect-
site concentration of 4 ng/ml using a Base Primea pump
(Fresenius-VialW, Brezins, France). The concentration of
4 ng/ml was chosen in view of previous data showing
that higher concentrations can be associated with
hypotension and bradycardia [14-17]. Ten minutes later,
the endotracheal fiberopticbronchoscopic procedure was
started (T2) (FB 0-FB 20). BIS was recorded until 10
minutes after the end of the procedure (T3) (PF 0-PF
10) (Figure 1).
All statistical analysis of data was performed by using
StatView software. Results were calculated for groups of
20 patients, following a previous study [6], to obtain a
50 % decrease in the BIS value after tracheal suction in
treated patients with a power of 80 % and α of 0.05.
Results were expressed as mean (±SD), and all data were
tested for normal distribution by the Kolmogorov-
Smirnoff test. Differences between the pre-procedure
and maximum BIS values for a given fiberoptic bron-
choscopy were compared between the two groups by
Student’s t test. BIS, heart rate (HR), invasive mean arter-
ial pressure (MAP), SpO2, and CO2 for each time and
changes of these parameters during the procedure were
analyzed using an one-way (or two-way) ANOVA for
repeated measures analysis.Results and discussion
Demographic data
Forty patients presenting criteria for ARDS defined by
the American-European consensus conference [18] were
included in this study between January 2008 and January
2009. One patient was excluded because of missing data.
No adverse effects related to Remifentanil infusion oc-
curred. There were no differences in age, weight, height,
gender, length of sedation, or median dose of midazolam
Table 1 Demographic data (mean± SD)
Placebo group Remifentanil group p
Age (yr) 56 ± 18 51 ± 17 0.2
Apache score 17 ± 12 15 ± 9 0.5
Ratio male/female 18/2 17/3 0.1
Weight (kg) 72 ± 29 78 ± 14 0.2
Height (cm) 156± 54 175 ± 7 0.2
Length of sedation before fiberoptic act (days) 3 ± 2 4 ± 3 0.1
Median Midazolam dose before procedure (mg/h) 11 ± 3 13 ± 4 0.2
Median Fentanyl dose before procedure (μg/h) 150± 50 165 ± 45 0.2
Maximum BIS variation during procedure 15 ± 14 12 ± 10 0.5
Median total dose of Remifentanil during procedure(μg) 142± 95 155 ± 70 0.3
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(Table 1). All of the patients had SAS and BPS scores of
1 and 3, respectively, before the use of muscle relaxant.
The overall agreement between BIS value and clinical
sedation assessment made with SAS and BPS was evalu-
ated. All the patients had deep level of sedation con-
trolled by SAS and BPS before procedure but high BIS
values (>60) were present in nine cases. BIS values
decreased lower than 60 after the administration of atra-
curium agent for all patients.
Physiologic recording
The median recording time during the procedure was
12 ± 4 min, with no difference between the groups. Heart
rates and mean arterial pressure were comparable be-
tween the placebo and Remifentanil groups during fiber-
optic bronchoscopy procedure (Figures 2 and 3). We
observed no SpO2 and CO2 variations during procedure.
BIS recording
The mean BIS values before the fiberoptic bronchoscopy
were not significantly different between the two groups:Figure 2 Mean heart rate (±SD) recorded each minute during
procedure.36.2± 11.9 vs. 35.8± 10.9 (p> 0.05) (Table 2). Similarly, we
observed no differences between the two groups in the
variation of the BIS value during the procedure (Figure 4).
Specifically, relative to the values determined before the
procedure, neither BIS nor maximum BIS variation were
different during the fiberoptic bronchoscopy, between the
two groups (15 ± 14 and 12± 10; p> 0.05; Figure 5).
Discussion
We report in this study that adjunctive boluses of remi-
fentanil are not necessary to prevent acute pain in
deeply sedated patient.
Protocolized optimized sedation and pain control in
the intensive care unit (ICU) can help to reduce dur-
ation of mechanical ventilation and length of stay in
ICU and hospital by reducing drug consumption [4,19].
However, it could be not sufficient to provide an ad-
equate analgesia during an acute painful care. Indeed,
Payen et al. described a rising of BPS during procedure
in patient under correct level of sedation [5].
Optimization of analgesic control, by adjunctive therapyFigure 3 Mean arterial pressure (±SD) recorded each minute
during procedure.




36 ± 12 36 ± 11 >0.05
Maximum BIS value
during procedure
53 ± 8 54± 11 >0.05
BIS value post
fiberoptic bronchoscopy
42 ± 6 46± 9 >0.05
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http://www.annalsofintensivecare.com/content/2/1/29for example, could be needed to impair the risk of post-
traumatic stress. Remifentanil, because of its pharmaco-
logic properties could be a very interesting approach.
This short-acting drug could protect the patient during
procedure without increasing the risk of oversedation
and consequences. In this study, we did not observe dif-
ferences in the variation of BIS values, as a surrogate for
analgesia evaluation, between the Remifentanil and pla-
cebo groups in mechanically ventilated, deeply sedated
patients during a fiberoptic bronchoscopy. Moreover,
BIS value did not change over time in both groups. We
also do not observe significant difference between pla-
cebo and Remifentanil group according to PAM and
heart rate. Heart rate is always higher in the placebo
group than in the remifentanil one, which could be
explained by direct chronotropic negative effect of Remi-
fentanil. The absence of BIS variation observed duringFigure 4 Box plot of BIS variation during procedure with mean (box p
maximum values and outliers. C10 10 mn after the myorelaxant injectionthe procedure could be explained by different ways. The
very low values recorded at the beginning of the proced-
ure can limit the impact of adjunctive therapy. Indeed,
we choose to study a particular group of patients need-
ing deep sedation for procedure. We may hypothesize
that deep sedation conducted to low initial BIS value,
leading to blunt significant variation in BIS value. Statis-
tically, an expected decrease in BIS value of 50 %, used
in anterior studies, is probably overestimated in this par-
ticular setting of deep sedated patients, and the sample
size could be underevaluated. Tolerance to fentanyl
developed before the procedure could limit the inter-
pretation of results, but length of sedation before pro-
cedure was short and dose was controlled by pain scale.
Furthermore, no signs of opioids tolerance were devel-
oped by patients. We can also hypothesize that the level
of pain is not sufficient but previous study described
fiberoptic examination as one of the most painful pro-
cedure [1]. Remifentanil doses could not be enough effi-
cient, but the absence of BIS variation in the placebo
group is not in accordance with this hypothesis.
In particular, critically ill conditions, such as patients
with brain trauma or respiratory failure, or for care pro-
cedure (fiberoptic bronchoscopy, tracheotomy. . .),
neuromuscular blocking agents administration is recom-
mended making the use of sedation scale scores, such as
the Behavioral Pain Scale (BPS) [5], impossible.lot) with median, interquartile (25th–75th), minimum and
.
Figure 5 Maximum BIS variation during fiberoptic bronchoscopy (mean± SD).
Quintard et al. Annals of Intensive Care 2012, 2:29 Page 5 of 6
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anesthesia in the operating room [13,20,21], could be an
approach. In an experimental study of healthy volun-
teers, adjunctive opioids to volatile agents-based
anesthesia increases clinical sedation but has no impact
on BIS value. However, patients did not suffer from
acute painful procedure [22]. In ICU, BIS use remains
controversial because of the high level of variability of
this parameter as described in our study (Figure 4),
which led us to study the variation of this rather isolated
value. Some authors have concluded that the most re-
cent version of BIS—BIS XP—is useful in the ICU set-
ting for assessing sedation [23], whereas others do not
share this view [24]. The use of BIS monitoring to assess
pain in our study could be criticized, but it was shown
to be sensitive to nociceptive stimuli in critically ill,
sedated patients [6,25]. Brocas et al. were able to blunt
BIS variations by adding a bolus of a short-acting opioid
to sedated patients before endotracheal suction. Other
studies have described similar results with other opioids
[17]. In accordance with these results, and with the
proposition of French consensus on sedation in the ICU,
we decided to use this device to evaluate the level of
pain of our critically ill patients [12].Conclusions
Our study shows that in deeply sedated patients receiving
analgesic support based on a scale score, additional adminis-
tration of short-acting analgesic drug, such as Remifentanil,
does not seems to be necessary for acute pain control
assessed by BIS variation. These data should be studied fur-
ther in a population of patients who need less sedation.Appendix
A.1. Riker sedation-agitation scale (SAS)
A.1.1. Score term descriptor
7 Dangerous Agitation Pulling at ET tube, trying to
remove catheters, climbing over bedrail, striking at
staff, thrashing side-to-side
6 Very Agitated Requiring restraint and frequent
verbal reminding of limits, biting ETT
5 Agitated Anxious or physically agitated, calms to
verbal instructions
4 Calm and Cooperative Calm, easily arousable,
follows commands
3 Sedated Difficult to arouse but awakens to verbal
stimuli or gentle shaking, follows simple commands
but drifts off again
2 Very Sedated Arouses to physical stimuli but does
not communicate or follow commands, may move
spontaneously
1 Unarousable Minimal or no response to noxious
stimuli, does not communicate or follow commandsAbbreviations
SAS: Sedation agitation scale; BPS: Behavioral pain scale; BIS: Bispectral index.Competing interests
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